Cover Image

Gene expression-based prediction of pazopanib efficacy in sarcoma

The multi-receptor tyrosine kinase inhibitor pazopanib is approved for the treatment of advanced soft-tissue sarcoma and has also shown activity in other sarcoma subtypes. However, its clinical efficacy is highly variable, and no reliable predictors exist to select patients who are likely to benefit...

Full description

Saved in:
Bibliographic Details
Main Authors: Heilig, Christoph E. (Author) , Laßmann, Andreas (Author) , Mughal, Sadaf S. (Author) , Mock, Andreas (Author) , Pirmann, Sebastian (Author) , Teleanu, Maria-Veronica (Author) , Renner, Marcus (Author) , Andresen, Carolin (Author) , Köhler, Bruno Christian (Author) , Aybey, Bogac (Author) , Bauer, Sebastian (Author) , Siveke, Jens T. (Author) , Hamacher, Rainer (Author) , Folprecht, Gunnar (Author) , Richter, Stephan (Author) , Schröck, Evelin (Author) , Brandts, Christian Hubertus (Author) , Ahrens, Marit (Author) , Hohenberger, Peter (Author) , Egerer, Gerlinde (Author) , Kindler, Thomas (Author) , Boerries, Melanie (Author) , Illert, Anna L. (Author) , von Bubnoff, Nikolas (Author) , Apostolidis, Leonidas (Author) , Jost, Philipp J. (Author) , Westphalen, C. Benedikt (Author) , Weichert, Wilko (Author) , Keilholz, Ulrich (Author) , Klauschen, Frederick (Author) , Beck, Katja (Author) , Winter, Ulrike (Author) , Richter, Daniela (Author) , Möhrmann, Lino (Author) , Bitzer, Michael (Author) , Schulze-Osthoff, Klaus (Author) , Brors, Benedikt (Author) , Mechtersheimer, Gunhild (Author) , Kreutzfeldt, Simon (Author) , Heining, Christoph (Author) , Lipka, Daniel (Author) , Stenzinger, Albrecht (Author) , Schlenk, Richard Friedrich (Author) , Horak, Peter (Author) , Glimm, Hanno (Author) , Hübschmann, Daniel (Author) , Fröhling, Stefan (Author)
Format: Article (Journal)
Language:English
Published: 25 June 2022
In: European journal of cancer
Year: 2022, Volume: 172, Pages: 107-118
ISSN:1879-0852
DOI:10.1016/j.ejca.2022.05.025
Online Access:Resolving-System, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.ejca.2022.05.025
Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S0959804922003045
Get full text
Author Notes:Christoph E. Heilig, Andreas Laßmann, Sadaf S. Mughal, Andreas Mock, Sebastian Pirmann, Veronica Teleanu, Marcus Renner, Carolin Andresen, Bruno C. Köhler, Bogac Aybey, Sebastian Bauer, Jens T. Siveke, Rainer Hamacher, Gunnar Folprecht, Stephan Richter, Evelin Schröck, Christian H. Brandts, Marit Ahrens, Peter Hohenberger, Gerlinde Egerer, Thomas Kindler, Melanie Boerries, Anna L. Illert, Nikolas von Bubnoff, Leonidas Apostolidis, Philipp J. Jost, C. Benedikt Westphalen, Wilko Weichert, Ulrich Keilholz, Frederick Klauschen, Katja Beck, Ulrike Winter, Daniela Richter, Lino Möhrmann, Michael Bitzer, Klaus Schulze-Osthoff, Benedikt Brors, Gunhild Mechtersheimer, Simon Kreutzfeldt, Christoph Heining, Daniel B. Lipka, Albrecht Stenzinger, Richard F. Schlenk, Peter Horak, Hanno Glimm, Daniel Hübschmann, Stefan Fröhling
Description
Summary:The multi-receptor tyrosine kinase inhibitor pazopanib is approved for the treatment of advanced soft-tissue sarcoma and has also shown activity in other sarcoma subtypes. However, its clinical efficacy is highly variable, and no reliable predictors exist to select patients who are likely to benefit from this drug.
Item Description:Gesehen am 04.10.2021
Physical Description:Online Resource
ISSN:1879-0852
DOI:10.1016/j.ejca.2022.05.025

Similar Items